Health Condition 1: J449- Chronic obstructive pulmonary disease, unspecified
Conditions
Interventions
None listed
Sponsors
TREAT Asia amfAR The Foundation for AIDS Research through a grant from the US NIH
BJ Government Medical College
Eligibility
Inclusion criteria
Inclusion criteria: a. Men, women, and transgender persons known to be PLHIV �18 years of age. (Note: Participants must be able to show proof that they are living with HIV, either by having a unique treatment number associated with the BJGMC-SGH ART center or a government provided HIV treatment book. A separate HIV test will not be performed in the study) b. Willingness to undergo at least one chest NCCT. c. Ability of the participant to provide informed consent. (Note: Illiterate participants will be enrolled based on local regulatory policies, with appropriate provisions for informed consent)
Exclusion criteria
Exclusion criteria: a. Unwillingness to undergo at least one chest NCCT. b. Having undergone a computed tomography (CT) of any part of the body, positron emission tomography (PET) or interventional radiology procedure (coronary angiography, angioplasty, etc.) within one year prior to the anticipated enrollment date. c. Men, women or transgender PLHIV with cognitive, hearing or language impairment. d. Men, women or transgender persons with unknown HIV status. e. Men, women or transgender PLHIV with a history of lung cancer or having received treatment for lung cancer in the past. f. Pregnant women. g. Inability/ Unwillingness to provide informed consent.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| a. Prevalent cases of lung nodules b. Incident cases of lung nodulesTimepoint: a. end of 4th year b. end of 3rd year | — |
Secondary
| Measure | Time frame |
|---|---|
| a. Overall prevalence of chronic obstructive pulmonary disease (COPD) b. Incident cases of COPD c. Overall prevalence of interstitial lung disease (ILD) d. Overall prevalence of pulmonary hypertension (PH) e. Overall incidence of PH f. Diffusion lung capacity of carbon monoxide (DLCO) g. Fractional excretion of nitric oxide (FENO) Timepoint: a.end of 4th year b.end of the 4th year, accounting for time on follow-up c. end of 4th year d.end of 3rd year e. end of 3rd year f. 1st year, 2nd year g. 1st year, 2nd year | — |
Countries
India
Contacts
Public ContactDr Nishi Suryavanshi
BJ Medical College Clinical trial unit
Outcome results
None listed